ALNYLAM PHARMACEUTICALS, INC.

ALNY

ALNYLAM PHARMACEUTICALS, INC.

ALNY

Insider Sentiment (TTM):

Last Purchase:2024-10-17Last Sale:2026-06-01Shares Purchased (TTM):0Shares Sold (TTM):188,067

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:114,727,981Shares Outstanding:131,004,000Institutional Ownership Pct.:87.58%

Earnings Market Reaction:

Filing Date:2026-02-12Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Pharmaceutical Preparations

LLY JNJ ABBV MRK ABT PFE

ALNYLAM PHARMACEUTICALS, INC. (ALNY) — SEC Financial Statements & Analysis

ALNYLAM PHARMACEUTICALS, INC. (ALNY) files its annual 10-K and quarterly 10-Q reports directly with the SEC. The financial data below is sourced as-filed from EDGAR — balance sheet, income statement, and cash flow as reported, without normalization or third-party adjustments.

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	1,657	1,490	1,114	1,020	966	1,100	968	682	813	1,033	658	672
Available For Sale Securities Debt Securities Curr…	1,251	1,234	1,744	1,605	1,720	1,672	1,646	1,678	1,616	1,363	1,372	1,373
Equity Securities Fv Ni	0	0	0	7	8	8	10	11	11	10	27	26
Accounts Receivable Net Current	778	965	567	418	405	354	309	321	328	325	221	219
Inventory Net	83	75	72	66	79	76	84	94	89	96	100	132
Prepaid Expense And Other Assets Current	282	188	147	152	117	145	155	202	126	158	145	119
Assets Current	4,051	3,953	3,644	3,268	3,295	3,355	3,173	2,989	2,983	2,985	2,524	2,541
Property Plant And Equipment Net	513	502	500	499	503	507	517	523	526	526	527	523
Operating Lease Right Of Use Asset	195	191	192	197	191	196	198	195	200	203	209	215
Deferred Income Tax Assets Net	126	99	104	107	117	-	-	-	10	-	-	-
Restricted Investments Noncurrent	22	51	69	69	69	69	49	49	49	49	49	49
Other Assets Noncurrent	59	56	57	74	65	78	72	67	62	75	93	63
Assets	4,966	4,852	4,566	4,214	4,240	4,205	4,010	3,824	3,830	3,839	3,402	3,392
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	116	118	102	97	88	71	74	78	56	74	60	62
Accrued Liabilities Current	1,080	1,154	919	704	794	946	809	699	713	713	599	509
Operating Lease Liability Current	46	45	46	46	42	42	42	42	42	42	42	43
Contract With Customer Liability Current	5	3	15	28	55	71	69	77	103	77	55	36
Derivative Liabilities Current	0	121	121	118	94	-	-	-	-	-	-	-
Liabilities Current	1,466	1,555	1,301	1,076	1,186	1,221	1,055	942	968	950	789	673
Operating Lease Liability Noncurrent	225	223	224	230	230	236	239	238	243	248	253	259
Contract With Customer Liability Noncurrent	-	-	-	-	0	1	2	186	188	196	194	191
Convertible Debt Noncurrent	1,008	1,040	1,027	1,026	1,025	1,024	1,023	1,022	1,021	1,020	1,019	1,018
Derivative Liabilities Noncurrent	0	440	408	422	393	-	-	-	-	-	-	-
Other Liabilities Noncurrent	8	10	11	6	5	357	350	320	308	281	257	224
Liabilities	4,177	4,618	4,315	4,098	4,173	4,173	4,013	4,044	4,051	4,005	3,811	3,651
Preferred Stock Value Outstanding	-	-	-	-	-	-	-	-	0	-	-	-
Stockholders Equity
Common Stock Value Outstanding	-	-	-	-	-	-	-	-	1	-	-	-
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	1	1	1	1	1	1	1	1	1	1	1	1
Additional Paid In Capital Common Stock	7,510	7,415	7,691	7,497	7,388	7,260	7,123	6,882	6,811	6,737	6,647	6,522
Accumulated Other Comprehensive Income Loss Net Of…	-20	-22	-30	-38	-35	-25	-35	-27	-23	-32	-37	-39
Retained Earnings Accumulated Deficit	-6,703	-7,160	-7,412	-7,345	-7,288	-7,204	-7,092	-7,076	-7,010	-6,872	-7,019	-6,743
Stockholders Equity	789	234	251	115	67	32	-3	-219	-221	-166	-408	-259
Liabilities And Stockholders Equity	4,966	4,852	4,566	4,214	4,240	4,205	4,010	3,824	3,830	3,839	3,402	3,392
Preferred Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	5
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Common Stock Shares Authorized	250	250	250	250	250	250	250	250	250	250	250	250
Common Stock Shares Issued	132	132	131	130	129	129	128	126	126	125	125	124
Shares Outstanding	132	132	131	130	129	129	128	126	126	125	125	124

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2025	13.65%	21.39%	25.63%	15.84%	15.63%	22.80%	-2.93%	-10.97%	-20.08%	3.95%	3.36%	-4.01%
2024	-1.70%	10.24%	58.23%	1.50%	1.96%	10.17%	-8.14%	-7.93%	-7.62%	-7.69%	-11.00%	-2.08%
2023	-8.34%	-6.18%	-2.59%	-0.44%	-9.76%	-14.89%	0.86%	18.26%	13.93%	1.62%	4.16%	3.32%
2022	-	-	-	-	-	-	-	-	-	-5.50%	3.91%	4.65%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 50+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31
Liquidity Ratios
Current Ratio	2.76	2.54	2.80	3.04	2.78	2.75	3.01	3.17	3.08	3.14	3.20	3.77
Quick Ratio	2.51	2.37	2.63	2.84	2.61	2.57	2.78	2.86	2.86	2.88	2.89	3.40
Working Capital	2.58B	2.40B	2.34B	2.19B	2.11B	2.13B	2.12B	2.05B	2.01B	2.04B	1.74B	1.87B
Leverage & Debt
Debt to Equity	5.29	19.74	17.22	35.50	62.20	128.97	-1,308.35	-18.44	-18.36	-24.15	-9.34	-14.08
Interest Coverage TTM	-	-	-	-	-5.02	-2.83	1.05	-1.38	-2.33	-2.96	-6.36	-5.53
Debt Ratio	0.84	0.95	0.95	0.97	0.98	0.99	1.00	1.06	1.06	1.04	1.12	1.08
Efficiency & Turnover
Asset Turnover TTM	0.81	0.71	0.57	0.58	0.56	0.52	0.63	0.56	0.50	0.47	0.37	0.34
Days Sales Outstanding TTM	58.13	74.97	64.98	57.47	59.51	59.18	41.27	49.27	56.47	54.00	53.52	60.01
Receivables Turnover TTM	6.28	4.87	5.62	6.35	6.13	6.17	8.84	7.41	6.46	6.76	6.82	6.08
Per Share Metrics
Diluted EPS TTM	2.33	0.32	-2.44	-2.08	-2.18	-2.58	-0.58	-2.63	-3.52	-3.88	-8.53	-8.58
Free Cash Flow Per Share TTM	3.55	1.68	-0.40	-0.58	-0.33	0.12	2.52	1.01	0.34	-0.53	-4.34	-4.87
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	81.77%	84.05%	83.88%	86.28%	86.37%	86.83%	88.34%	85.95%	85.33%	85.94%	83.88%	86.17%
Operating Profit Margin TTM	13.51%	8.25%	-7.32%	-4.91%	-7.87%	-8.98%	4.38%	-8.78%	-15.43%	-20.56%	-66.78%	-68.93%
Net Profit Margin TTM	8.45%	1.36%	-12.96%	-11.49%	-12.37%	-15.86%	-3.11%	-16.58%	-24.08%	-29.58%	-85.95%	-93.13%
Growth Metrics
Net Revenue Growth (1Y)	65.19%	53.24%	5.01%	17.21%	22.97%	21.54%	89.46%	75.20%	76.23%	91.32%	53.97%	54.60%
Net Income Growth (1Y)	-212.79%	-113.11%	337.46%	-18.78%	-36.82%	-34.83%	-93.14%	-68.82%	-61.08%	-56.87%	8.44%	19.27%
EPS Growth (1Y)	-209.91%	-112.83%	324.42%	-21.00%	-38.18%	-36.54%	-93.25%	-69.32%	-62.08%	-57.92%	5.17%	15.70%
Valuation Metrics
P/E TTM	166.04	1,375.87	-133.49	-129.83	-107.99	-106.44	-422.21	-56.77	-54.31	-43.49	-22.26	-23.35
P/B	66.01	256.27	169.98	303.33	447.73	1,093.10	-10,041.12	-85.97	-108.36	-133.70	-58.02	-95.90
P/S TTM	14.03	18.67	17.30	14.91	13.36	16.88	13.14	9.41	13.08	12.87	19.14	21.74
Market Cap	52.09B	59.94B	42.60B	35.02B	30.04B	35.37B	30.80B	18.85B	23.91B	22.18B	23.68B	24.86B
Enterprise Value	52.09B	60.06B	42.51B	35.02B	31.11B	35.29B	30.85B	19.19B	24.11B	22.16B	24.04B	25.21B
Calculated Values
Free Cash Flow TTM	465.38M	221.36M	-52.09M	-75.39M	-42.59M	16.06M	318.87M	127.82M	41.95M	-66.56M	-540.68M	-604.65M
Net Debt	-3.82M	122.47M	-89.34M	3.32M	1.08B	-78.84M	51.50M	337.01M	205.89M	-15.40M	358.87M	343.48M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-01Sale

Owner: Pyott, David E I

Title: -

Shares: 3,830

Price/Share: $299.97

Value: $1,148,885.10

Shares Owned: 1,582

Relationship: Director

Ownership: Direct

2026-04-06Sale

Owner: Mclaughlin, Melissa

Title: Chief Human Resources Officer

Shares: 2,286

Price/Share: $329.24

Value: $752,642.64

Shares Owned: 9,443

Relationship: Officer

Ownership: Direct

2026-03-05Sale

Owner: Fitzgerald, Kevin Joseph

Title: CSO & EVP, Head of Research

Shares: 658

Price/Share: $323.98

Value: $213,178.84

Shares Owned: 20,569

Relationship: Officer

Ownership: Direct

2026-03-05Sale

Owner: Garg, Pushkal

Title: EVP Chief R&D

Shares: 2,404

Price/Share: $324.14

Value: $779,232.56

Shares Owned: 18,693

Relationship: Officer

Ownership: Direct

2026-03-04Sale

Owner: Poulton, Jeffrey V.

Title: EVP, Chief Financial Officer

Shares: 2,468

Price/Share: $322.38

Value: $795,633.84

Shares Owned: 61,805

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-01	Pyott, David E I	Director	-	Direct	Sale	3,830	299.97	$1,148,885.10	1,582	4
2026-04-06	Mclaughlin, Melissa	Officer	Chief Human Resources Officer	Direct	Sale	2,286	329.24	$752,642.64	9,443	4
2026-03-05	Fitzgerald, Kevin Joseph	Officer	CSO & EVP, Head of Research	Direct	Sale	658	323.98	$213,178.84	20,569	4
2026-03-05	Garg, Pushkal	Officer	EVP Chief R&D	Direct	Sale	2,404	324.14	$779,232.56	18,693	4
2026-03-04	Poulton, Jeffrey V.	Officer	EVP, Chief Financial Officer	Direct	Sale	2,468	322.38	$795,633.84	61,805	4
2026-03-04	Greenstreet, Yvonne	Director,Officer	Chief Executive Officer	Direct	Sale	2,933	322.38	$945,540.54	95,695	4
2026-03-04	Tanguler, Tolga	Officer	EVP, Chief Commercial Officer	Direct	Sale	2,309	322.38	$744,375.42	34,297	4
2026-03-03	Garg, Pushkal	Officer	EVP Chief R&D	Direct	Sale	1,775	319.44	$567,006.00	23,406	4
2026-03-03	Fitzgerald, Kevin Joseph	Officer	CSO & EVP, Head of Research	Direct	Sale	1,652	319.32	$527,516.64	21,860	4
2026-03-02	Greenstreet, Yvonne	Director,Officer	Chief Executive Officer	Direct	Sale	6,799	328.22	$2,231,567.78	98,628	4
2026-03-02	Tanguler, Tolga	Officer	EVP, Chief Commercial Officer	Direct	Sale	1,598	328.22	$524,495.56	36,606	4
2026-03-02	Poulton, Jeffrey V.	Officer	EVP, Chief Financial Officer	Direct	Sale	2,206	328.22	$724,053.32	64,273	4
2026-02-27	Garg, Pushkal	Officer	EVP Chief R&D	Direct	Sale	4,627	331.60	$1,534,313.20	22,129	4
2026-02-17	Fitzgerald, Kevin Joseph	Officer	CSO & EVP, Head of Research	Direct	Sale	2,041	331.96	$677,530.36	21,264	4
2026-02-13	Garg, Pushkal	Officer	EVP Chief R&D	Direct	Sale	2,242	310.08	$695,199.36	24,848	4
2026-02-13	Poulton, Jeffrey V.	Officer	EVP, Chief Financial Officer	Direct	Sale	2,242	310.08	$695,199.36	59,802	4
2026-02-13	Greenstreet, Yvonne	Director,Officer	Chief Executive Officer	Direct	Sale	6,958	310.08	$2,157,536.64	85,662	4
2026-02-13	Tanguler, Tolga	Officer	EVP, Chief Commercial Officer	Direct	Sale	1,959	310.08	$607,446.72	31,769	4
2026-01-13	Fitzgerald, Kevin Joseph	Officer	CSO & EVP, Head of Research	Direct	Sale	2,290	370.80	$849,132.00	21,264	4
2026-01-12	Tanguler, Tolga	Officer	EVP, Chief Commercial Officer	Direct	Sale	1,510	364.80	$550,848.00	29,728	4
2026-01-12	Poulton, Jeffrey V.	Officer	EVP, Chief Financial Officer	Direct	Sale	2,780	364.80	$1,014,144.00	57,465	4
2026-01-12	Greenstreet, Yvonne	Director,Officer	Chief Executive Officer	Direct	Sale	9,577	364.80	$3,493,689.60	78,411	4
2026-01-12	Garg, Pushkal	Officer	EVP Chief R&D	Direct	Sale	1,510	364.80	$550,848.00	22,511	4
2025-11-17	Fitzgerald, Kevin Joseph	Officer	CSO & EVP, Head of Research	Direct	Sale	12,128	456.70	$5,538,857.60	21,264	4
2025-11-13	Greenstreet, Yvonne	Director,Officer	Chief Executive Officer	Direct	Sale	10,000	451.86	$4,518,600.00	65,409	4
2025-10-03	Garg, Pushkal	Officer	EVP Chief R&D	Direct	Sale	3,022	452.05	$1,366,095.10	20,221	4
2025-10-02	Tanguler, Tolga	Officer	EVP, Chief Commercial Officer	Direct	Sale	1,405	452.32	$635,509.60	27,438	4
2025-10-02	Greenstreet, Yvonne	Director,Officer	Chief Executive Officer	Direct	Sale	8,924	452.32	$4,036,503.68	65,409	4
2025-10-02	Poulton, Jeffrey V.	Officer	EVP, Chief Financial Officer	Direct	Sale	3,821	452.32	$1,728,314.72	54,052	4
2025-10-02	Fitzgerald, Kevin Joseph	Officer	CSO & EVP, Head of Research	Direct	Sale	2,441	452.32	$1,104,113.12	25,231	4
2025-09-09	Reitan, Colleen F	Director	-	Direct	Sale	18,000	469.51	$8,451,180.00	775	4
2025-08-29	Tanguler, Tolga	Officer	EVP, Chief Commercial Officer	Direct	Sale	3,474	449.02	$1,559,895.48	25,992	4
2025-08-19	Garg, Pushkal	Officer	EVP Chief R&D	Direct	Sale	1,455	458.88	$667,670.40	20,221	4
2025-08-18	Fitzgerald, Kevin Joseph	Officer	CSO & EVP, Head of Research	Direct	Sale	1,396	452.31	$631,424.76	22,719	4
2025-08-18	Poulton, Jeffrey V.	Officer	EVP, Chief Financial Officer	Direct	Sale	2,274	452.31	$1,028,552.94	50,121	4
2025-08-18	Bonney, Michael W	Director	-	Direct	Sale	11,250	450.00	$5,062,500.00	16,804	4
2025-08-18	Greenstreet, Yvonne	Director,Officer	Chief Executive Officer	Direct	Sale	6,979	452.31	$3,156,671.49	56,221	4
2025-08-18	Tanguler, Tolga	Officer	EVP, Chief Commercial Officer	Direct	Sale	1,396	452.31	$631,424.76	29,466	4
2025-08-14	Ausiello, Dennis A	Director	-	Direct	Sale	31,448	437.26	$13,750,952.48	911	4
2025-06-02	Greenstreet, Yvonne	Director,Officer	Chief Executive Officer	Direct	Sale	19,297	306.00	$5,904,882.00	48,948	4
2025-05-15	Bonney, Michael W	Director	-	Direct	Sale	11,250	276.05	$3,105,562.50	16,804	4
2025-04-16	Reitan, Colleen F	Director	-	Direct	Sale	36	232.86	$8,382.96	0	4
2025-03-24	Pyott, David E I	Director	-	Direct	Sale	7,440	299.00	$2,224,560.00	136	4
2025-03-24	Garg, Pushkal	Officer	CMO & EVP Dev & Med Affairs	Direct	Sale	5,445	300.00	$1,633,500.00	20,221	4
2025-03-04	Fitzgerald, Kevin Joseph	Officer	CSO & EVP, Head of Research	Direct	Sale	844	241.20	$203,572.80	13,501	4
2025-03-04	Garg, Pushkal	Officer	CMO & EVP Dev & Med Affairs	Direct	Sale	808	241.12	$194,824.96	24,542	4
2025-03-03	Poulton, Jeffrey V.	Officer	EVP, Chief Financial Officer	Direct	Sale	1,264	245.33	$310,097.12	47,751	4
2025-03-03	Tanguler, Tolga	Officer	EVP, Chief Commercial Officer	Direct	Sale	471	244.82	$115,310.22	28,011	4
2025-03-03	Greenstreet, Yvonne	Director,Officer	Chief Executive Officer	Direct	Sale	3,877	245.33	$951,144.41	98,635	4
2025-02-28	Fitzgerald, Kevin Joseph	Officer	CSO & EVP, Head of Research	Direct	Sale	496	240.70	$119,387.20	12,385	4
2025-02-28	Tanguler, Tolga	Officer	EVP, Chief Commercial Officer	Direct	Sale	513	240.70	$123,479.10	14,345	4
2025-02-28	Greenstreet, Yvonne	Director,Officer	Chief Executive Officer	Direct	Sale	2,900	240.70	$698,030.00	84,547	4
2025-02-28	Poulton, Jeffrey V.	Officer	EVP, Chief Financial Officer	Direct	Sale	796	240.70	$191,597.20	33,898	4
2025-02-28	Garg, Pushkal	Officer	CMO & EVP Dev & Med Affairs	Direct	Sale	935	240.70	$225,054.50	12,962	4
2025-02-18	Garg, Pushkal	Officer	CMO & EVP Dev & Med Affairs	Direct	Sale	1,548	254.26	$393,594.48	11,989	4
2025-02-18	Fitzgerald, Kevin Joseph	Officer	CSO & EVP, Head of Research	Direct	Sale	1,440	254.95	$367,128.00	12,881	4
2025-02-14	Poulton, Jeffrey V.	Officer	EVP, Chief Financial Officer	Direct	Sale	967	258.13	$249,611.71	32,786	4
2025-02-14	Greenstreet, Yvonne	Director,Officer	Chief Executive Officer	Direct	Sale	1,213	258.13	$313,111.69	81,526	4
2025-01-27	Garg, Pushkal	Officer	CMO & EVP Dev & Med Affairs	Direct	Sale	52,592	285.00	$14,988,720.00	11,989	4
2025-01-23	Sharp, Phillip A	Director	-	Direct	Sale	11,250	275.00	$3,093,750.00	0	4
2024-12-12	Garg, Pushkal	Officer	CMO & EVP Dev & Med Affairs	Direct	Sale	1,752	251.62	$440,838.24	15,705	4
2024-11-27	Fitzgerald, Kevin Joseph	Officer	CSO & EVP, Head of Research	Direct	Sale	1,531	252.59	$386,715.29	12,881	4
2024-11-26	Greenstreet, Yvonne	Director,Officer	Chief Executive Officer	Direct	Sale	5,219	250.35	$1,306,576.65	78,880	4
2024-11-26	Tanguler, Tolga	Officer	EVP, Chief Commercial Officer	Direct	Sale	1,469	250.35	$367,764.15	13,191	4
2024-11-26	Garg, Pushkal	Officer	CMO & EVP Dev & Med Affairs	Direct	Sale	1,682	250.35	$421,088.70	17,457	4
2024-11-26	Poulton, Jeffrey V.	Officer	EVP, Chief Financial Officer	Direct	Sale	1,682	250.35	$421,088.70	30,644	4
2024-10-17	Reitan, Colleen F	Director	-	Direct	Purchase	4	302.67	$1,210.68	36	4
2024-08-20	Greenstreet, Yvonne	Director,Officer	Chief Executive Officer	Direct	Sale	15,000	280.00	$4,200,000.00	73,441	4
2024-08-12	Fitzgerald, Kevin Joseph	Officer	CSO & EVP, Head of Research	Direct	Sale	22,025	271.83	$5,987,055.75	12,881	4
2024-08-06	Ausiello, Dennis A	Director	-	Direct	Sale	20,250	262.79	$5,321,497.50	136	4
2024-08-01	Greenstreet, Yvonne	Director,Officer	Chief Executive Officer	Direct	Sale	15,148	270.00	$4,089,960.00	73,441	4
2024-07-11	Greenstreet, Yvonne	Director,Officer	Chief Executive Officer	Direct	Sale	7,093	261.00	$1,851,273.00	73,441	4
2024-06-25	Fitzgerald, Kevin Joseph	Officer	CSO & EVP, Head of Research	Direct	Sale	1,198	229.42	$274,845.16	14,181	4
2024-06-25	Garg, Pushkal	Officer	CMO & EVP Dev & Med Affairs	Direct	Sale	2,103	229.42	$482,470.26	15,609	4
2024-06-25	Tanguler, Tolga	Officer	EVP, Chief Commercial Officer	Direct	Sale	1,605	229.42	$368,219.10	11,660	4
2024-06-25	Poulton, Jeffrey V.	Officer	EVP, Chief Financial Officer	Direct	Sale	1,605	229.42	$368,219.10	28,892	4
2024-06-25	Schulman, Amy W	Director	-	Direct	Sale	8,500	240.00	$2,040,000.00	8,436	4
2024-06-25	Greenstreet, Yvonne	Director,Officer	Chief Executive Officer	Direct	Sale	8,301	229.42	$1,904,415.42	80,534	4
2024-06-24	Pyott, David E I	Director	-	Direct	Sale	32,450	221.00	$7,171,450.00	136	4
2024-05-29	Schulman, Amy W	Director	-	Direct	Sale	21,700	148.97	$3,232,649.00	8,436	4
2024-02-29	Sharp, Phillip A	Director	-	Direct	Sale	30,000	153.11	$4,593,300.00	0	4
2024-02-28	Garg, Pushkal	Officer	CMO & EVP Dev & Med Affairs	Direct	Sale	574	156.35	$89,744.90	8,666	4
2024-02-28	Tanguler, Tolga	Officer	EVP, Chief Commercial Officer	Direct	Sale	501	156.35	$78,331.35	5,236	4
2024-02-28	Poulton, Jeffrey V.	Officer	EVP, Chief Financial Officer	Direct	Sale	574	156.35	$89,744.90	19,478	4
2024-02-28	Franchini, Indrani Lall	Officer	EVP, CLO & Secretary	Direct	Sale	329	156.35	$51,439.15	4,133	4
2024-02-28	Greenstreet, Yvonne	Director,Officer	Chief Executive Officer	Direct	Sale	2,932	156.35	$458,418.20	48,128	4
2024-02-16	Tanguler, Tolga	Officer	EVP, Chief Commercial Officer	Direct	Sale	1,009	148.26	$149,594.34	4,070	4
2024-02-16	Poulton, Jeffrey V.	Officer	EVP, Chief Financial Officer	Direct	Sale	1,007	148.26	$149,297.82	18,144	4
2024-02-16	Greenstreet, Yvonne	Director,Officer	Chief Executive Officer	Direct	Sale	7,030	148.26	$1,042,267.80	45,139	4
2024-02-16	Garg, Pushkal	Officer	CMO & EVP Dev & Med Affairs	Direct	Sale	1,308	148.26	$193,924.08	7,332	4
2024-02-02	Franchini, Indrani Lall	Officer	EVP, CLO & Secretary	Direct	Sale	1,591	171.18	$272,347.38	3,584	4
2023-12-27	Bonney, Michael W	Director	-	Direct	Sale	30,000	195.00	$5,850,000.00	16,029	4
2023-08-07	Garg, Pushkal	Officer	CMO & EVP Dev & Med Affairs	Direct	Sale	4,166	184.52	$768,710.32	4,345	4
2023-08-04	Poulton, Jeffrey V.	Officer	EVP, Chief Financial Officer	Direct	Sale	3,460	186.95	$646,847.00	15,873	4
2023-08-04	Greenstreet, Yvonne	Director,Officer	Chief Executive Officer	Direct	Sale	4,057	186.95	$758,456.15	35,216	4
2023-08-04	Vaishnaw, Akshay	Officer	President	Direct	Sale	4,057	186.95	$758,456.15	22,774	4
2023-08-03	Bonney, Michael W	Director	-	Direct	Sale	6,448	184.70	$1,190,945.60	16,029	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

87.58%

Inst. Shares: 114,727,981

Shares Outstanding: 131,004,000

2025-12-31

95.13%

Inst. Shares: 124,620,302

Shares Outstanding: 131,004,000

2025-09-30

94.64%

Inst. Shares: 124,401,451

Shares Outstanding: 131,447,000

2025-06-30

94.52%

Inst. Shares: 123,467,881

Shares Outstanding: 130,628,000

2025-03-31

90.47%

Inst. Shares: 117,323,533

Shares Outstanding: 129,676,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	114,727,981	131,004,000	87.58%
2025-12-31	124,620,302	131,004,000	95.13%
2025-09-30	124,401,451	131,447,000	94.64%
2025-06-30	123,467,881	130,628,000	94.52%
2025-03-31	117,323,533	129,676,000	90.47%
2024-12-31	118,326,930	127,651,000	92.70%
2024-09-30	113,412,347	128,590,000	88.20%
2024-06-30	111,656,136	126,733,000	88.10%
2024-03-31	103,979,427	126,138,000	82.43%
2023-12-31	107,901,354	124,906,000	86.39%
2023-09-30	106,701,976	125,220,000	85.21%
2023-06-30	108,058,674	124,659,000	86.68%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

ALNYLAM PHARMACEUTICALS, INC. (ALNY) — SEC Financial Statements & Analysis

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.